Summary
Selenium supplementation has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Sarcopenia. ClinicalTrials.gov lists 1 registered trial linking Selenium supplementation to Sarcopenia: 1 is currently recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 240 participants. Registered activity dates to 2025. No published literature item is linked to Selenium supplementation and Sarcopenia in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Sarcopenia ranks 82 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 8.0 (trials 3.0, literature 0.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 1 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 0 |
| Agent type | Supplement |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Reversing decline in aging muscles: expected trends, impacts and remedies · Halma M, Marik P, Varon J, Tuszynski J · 2025 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05324475 | Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. 2025 | recruiting | Not applicable | 240 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: Reversing decline in aging muscles: expected trends, impacts and remedies · Halma M, Marik P, Varon J, Tuszynski J · 2025.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Selenium supplementation approved for Sarcopenia?
Selenium supplementation has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Sarcopenia. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Selenium supplementation in clinical trials for Sarcopenia?
ClinicalTrials.gov lists 1 registered trial linking Selenium supplementation to Sarcopenia: 1 is currently recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 240 participants. Registered activity dates to 2025.
What does the evidence show for Selenium supplementation in Sarcopenia?
Trials of Selenium supplementation in Sarcopenia are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.